Performance evaluation of a fully closed real-time PCR platform for the detection of KRAS p.G12C mutations in liquid biopsy of patients with non-small cell lung cancer.
lung neoplasms
molecular
molecular biology
pathology
Journal
Journal of clinical pathology
ISSN: 1472-4146
Titre abrégé: J Clin Pathol
Pays: England
ID NLM: 0376601
Informations de publication
Date de publication:
May 2022
May 2022
Historique:
received:
13
01
2021
revised:
08
02
2021
accepted:
09
02
2021
pubmed:
3
3
2021
medline:
23
4
2022
entrez:
2
3
2021
Statut:
ppublish
Résumé
Whenever tissue sample is not available, non-small cell lung cancer (NSCLC) biomarker testing is performed with liquid biopsy. The Kirsten rat sarcoma viral oncogene homolog (
Identifiants
pubmed: 33649142
pii: jclinpath-2021-207416
doi: 10.1136/jclinpath-2021-207416
doi:
Substances chimiques
Cell-Free Nucleic Acids
0
KRAS protein, human
0
Proto-Oncogene Proteins p21(ras)
EC 3.6.5.2
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
350-353Informations de copyright
© Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: GT reports personal fees (as speaker bureau or advisor) from Roche, MSD, Pfizer and Bayer, unrelated to the current work. UM received personal fees (as consultant and/or speaker bureau) from Boehringer Ingelheim, Roche, MSD, Amgen, Thermo Fisher Scientifics, Diaceutics, GSK, Merck and AstraZeneca, unrelated to the current work. The other authors have no other conflicts of interest to declare.